Harvard Bioscience (HBIO) Cash from Financing Activities (2010 - 2026)

Harvard Bioscience (HBIO) has reported Cash from Financing Activities for 17 consecutive years, with -$9000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 99.25% year-over-year to -$9000.0; the TTM figure through Mar 2026 stood at -$96000.0 (up 65.71% YoY), while the FY2025 annual figure was -$1.3 million, down 885.5% from the prior year.
• Cash from Financing Activities retreated to -$9000.0 in Q1 2026 per HBIO's latest filing, from $2.4 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $2.4 million in Q4 2025 and bottomed at -$4.1 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged -$964823.5 across 5 years, with a median of -$1.2 million in 2025.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 3177.66% — and 2025, when it jumped 280.47%.
• Harvard Bioscience's Cash from Financing Activities stood at -$2.7 million in 2022, then sank by 50.77% to -$4.1 million in 2023, then soared by 67.03% to -$1.4 million in 2024, then surged by 280.47% to $2.4 million in 2025, then sank by 100.37% to -$9000.0 in 2026.
• Business Quant data shows HBIO's Cash from Financing Activities at -$9000.0 in Q1 2026, $2.4 million in Q4 2025, and -$1.3 million in Q3 2025.